Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • March 21, 2019 8:23 AM | Anonymous

    March 21, 2019, MD Magazine 

    The U.S. Food and Drug Administration (FDA) has approved brexanolone injection (Zulresso) as the first therapy indicated for the treatment of postpartum depression (PPD) in adult women. The therapy, which was approved for intravenous (IV) use in women enrolled in the Zulresso REMS Program, will only be available through the program, and administered by a care provider in a certified healthcare facility. Women treated with the drug are administered a continuous 60-hour IV infusion. 

    Read more.

  • March 21, 2019 8:19 AM | Anonymous

    March 21, 2019, MedScape 

    Researchers have developed a simple, noninvasive, point-of-care paper test that measures misfolded proteins in a woman's urine and looks set to improve the diagnosis of preeclampsia

    Read more & sign up for free medical news from MedScape here.


  • March 20, 2019 8:45 AM | Anonymous

    March 19, 2019, MedPage Today 

    HONOLULU -- Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here. 

    Read more.

  • March 19, 2019 1:04 PM | Anonymous

    March 19, 2019, MedPage Today  

    Unconscious biases held by some clinicians about cervical cancer and the HPV vaccine could negatively impact quality of care and outcomes for patients, new research suggests. 

    Read more.

  • March 19, 2019 1:03 PM | Anonymous

    March 19, 2019, MedPage Today 

    Lack of response to a PARP inhibitor in epithelial ovarian cancer didn't necessarily mean patients were resistant to all such agents, a small retrospective study indicated. 

    Read more.

  • March 18, 2019 8:32 AM | Anonymous

    March 18, 2019, MedPage Today  

    Use of brachytherapy within 8 weeks improved survival for women with locally advanced cervical cancer, but this happened in just over a third of cases, and certain patient groups were less likely to receive the standard therapy at all, a pair of National Cancer Data Base (NCDB) studies found. 

    Read more.

  • March 15, 2019 8:30 AM | Anonymous

    March 15, 2019, MedPage  Today 

    Second trimester abortions became more common following the implementation of Texas House Bill 2, which dramatically restricted abortions in the state, researchers found. 

    Read more.

  • March 14, 2019 8:18 AM | Anonymous

    March 14, 2019, Ohio State University Wexner Medical Center  

    Researchers with The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center and Nationwide Children’s Hospital have found that a simple urine test can rapidly detect one of the world’s deadliest pregnancy-related conditions, which could have a major impact on global health.  

    Read more.


  • March 13, 2019 11:10 AM | Anonymous

    March 13, 2019, CNN via WebMD 

    The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer. The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported.

    Read more.

  • March 13, 2019 10:51 AM | Anonymous

    March 13, 2019, UDaily  

    Two University of Delaware researchers have developed a new approach to attack cancer, using two light-activated treatments that appear to be more effective together than when applied independently. More research is needed, but the findings point to promising new approaches against an especially challenging kind of cancer — triple negative breast cancer — which was the focus of their recent studies.  

    Read more.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
Powered by Wild Apricot Membership Software